Pfizer CEO says it's 'radical' to suggest pharma should forgo profits on COVID-19 vaccine: report Teladoc's virtual visits grow 200% in Q2, revenue reaches $241M as COVID-19 resurges J&J COVID-19 vaccine candidate protects monkeys after single dose Sanofi, GlaxoSmithKline pledge 60M doses of their recombinant COVID-19 shot to U.K. Cigna saw utilization 'closer to normal' in June, expects similar trends in July despite COVID-19 spikes Biopharma roundup: AZ grows, Lilly skids amid pandemic; Sorrento grabs rapid COVID-19 saliva test Healthcare roundup: CMS creates new codes for COVID-19 treatments, counseling Color's coronavirus self-test authorized to help reduce healthcare worker exposure Looking beyond COVID-19's spike protein for the next wave of vaccines Fewer than 10% of primary care practices have stabilized operations amid COVID-19 pandemic Lilly's new drugs hold steady amid the pandemic, but one migraine launch lags HIMSS pushes back 2021 conference to August Featured Story | By Arlene Weintraub Does the biopharma industry deserve to profit from the products they’re developing to end the COVID-19 pandemic? Pfizer CEO Albert Bourla has a strong opinion about that, and it differs from that of executives at GlaxoSmithKline, Johnson & Johnson and AstraZeneca, all of whom have taken not-for-profit approaches to COVID-19 vaccine development. read more |
| |
|---|
|
Top Stories By Heather Landi Teladoc continues to prosper from the boom in virtual care as revenue in the second quarter surged 85% to $241 million. The company reported total virtual visits increased 203% to 2.8 million during the second quarter. read more By Arlene Weintraub Scientists led by Beth Israel Deaconess Medical Center in Boston tested seven different COVID-19 vaccine candidates from J&J in nonhuman primates, landing on one that prevented the virus from infecting the animals' lungs with a single dose. The company plans to test both a one- and two-dose regimen in clinical trials. read more By Fraiser Kansteiner In early July, a British newspaper suggested that Sanofi and GlaxoSmithKline were edging closer to a $625M pact with the U.K. to supply up to 60 million COVID-19 vaccine doses. Now, the companies have officially pledged that 60 million—but the financial details remain under wraps. read more By Paige Minemyer Cigna generated $1.8 billion in profit during the second quarter, up from $1.4 billion in the prior-year quarter. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner AstraZeneca weathered the COVID-19 slowdown with strong oncology performance, while Eli Lilly took a second-quarter blow. Sorrento Therapeutics snagged a color-changing COVID-19 spit test. Researchers are exploring T cells as a crucial indicator of COVID-19 immunity. Plus, ExeVir is using llamas to make COVID-fighting antibodies. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Conor Hale The FDA has authorized Color’s coronavirus test to be performed wholly unmonitored, allowing people to collect their own samples without requiring any supervision, either in-person or over video, by a trained healthcare worker. read more By Angus Liu Most ongoing vaccine development efforts against the novel coronavirus focus on the spike protein on the surface of SARS-CoV-2. But a team led by immuno-oncology specialist TScan Therapeutics found that memory CD8+ T cells from recovered patients mainly target sites outside of the spike protein. read more By Heather Landi Nearly 9 in 10 primary care practices continue to face significant difficulties with COVID-19, including obtaining medical supplies, a recent survey found. Here's what primary care clinicians say they need from private insurers to help support them through the pandemic. read more By Eric Sagonowsky Eli Lilly lost $500 million in potential sales due to the pandemic, but it's still in a strong position, one analyst writes. New launches made up 54% of the company's overall sales, but migraine medicine Reyvow was highlighted as one laggard. read more By Heather Landi The Healthcare Information and Management Systems Society has pushed back its five-day annual conference to Aug. 9 in Las Vegas next year. read more |
